JAKARTA (REUTERS) – Indonesia’s drug regulator on Friday (April 30) approved a Covid-19 vaccine produced by China’s Sinopharm, which is due to be used in a private vaccination scheme under which companies can buy government-procured vaccines to inoculate their staff.
No detailed efficacy data of Sinopharm’s vaccine has been publicly released, but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said the vaccine was 79.34 per cent effective in preventing people from developing the disease, based on interim data.
This is a developing story.
Join ST’s Telegram channel here and get the latest breaking news delivered to you.
Source: Read Full Article